KQ Labs opens accelerator programme and announces LifeArc as a strategic partner
KQ Labs is now accepting applications for its third cohort of companies. Early stage data-driven health companies…
KQ Labs is now accepting applications for its third cohort of companies. Early stage data-driven health companies…
£10m in grants mean patient enrolment can begin immediately
Hubs aim to address challenges in progressing novel gene therapy research into early stage clinical trials
LifeArc provides £2m to the STOPCOVID project, which aims to test existing and experimental drugs to find a treatment for COVID-19
Today, LifeArc, a UK-based medical research charity, has created a £10 million fund to support research to…
The funding will support a two-year programme to develop and automate GyreOx’s proprietary drug discovery platform, MACRO.
The investment will help advance studies to validate polyproxin® molecules as potential drug candidates across a range of cancers.
Funding aims to progress strong discovery science to a point where additional substantive funding could be secured.
Translational research can turn promising science into new treatments for those with rare diseases. It’s why we…